Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies
April 30, 2024 07:00 ET
|
Replay Bio
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies Phase 1/2...
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma
March 11, 2024 07:00 ET
|
Replay Bio
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma Phase 1/2 clinical study of NY-ESO-1 TCR/IL-15 NK for relapsed...
Replay and its engineered NK cell therapy company Syena announce exclusive licensing agreement with National Institutes of Health for TCRs targeting cancer neoantigens
December 18, 2023 07:00 ET
|
Replay Bio
Replay and its engineered NK cell therapy company Syena announce exclusive licensing agreement with National Institutes of Health for TCRs targeting cancer neoantigens Replay and its...
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer
September 21, 2023 08:00 ET
|
Replay Bio
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer Collaboration leverages JURA Bio’s T cell receptor (TCR) discovery platform...
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for multiple myeloma
July 24, 2023 07:00 ET
|
Replay Bio
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for multiple myeloma Phase 1 study of NY-ESO-1 TCR/IL-15 NK...
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for sarcoma
June 20, 2023 07:00 ET
|
Replay Bio
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for sarcoma First-in-human Phase 1 study of NY-ESO-1...
Replay receives $1.5 million grant for its hypoimmunogenic technology platform
November 28, 2022 07:00 ET
|
Replay Bio
Replay receives $1.5 million grant for its hypoimmunogenic technology platform Replay developing uCell™, its universal, off-the-shelf, genomically rewritten, renewable cell source hypoimmunogenic...
Replay launches big DNA HSV gene therapy company, Telaria, focused on rare skin diseases
November 21, 2022 07:00 ET
|
Replay Bio
Replay launches big DNA HSV gene therapy company, Telaria, focused on rare skin diseases Second product company using Replay’s next-generation high payload capacity HSV delivery vector developed at...
SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19
September 08, 2020 03:00 ET
|
SpyBiotech
OXFORD, United Kingdom, Sept. 08, 2020 (GLOBE NEWSWIRE) -- SpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases, today announces that its...